Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;147(4):320-328.
doi: 10.1001/jamaoto.2020.5151.

Association of Prolonged-Duration Chemoprophylaxis With Venous Thromboembolism in High-risk Patients With Head and Neck Cancer

Kiranya E Tipirneni  1 , Lee Bauter  2 , Mark A Arnold  1 , Jason A Audlin  1 , Jesse Ryan  1 , Mark Marzouk  1
Affiliations

Association of Prolonged-Duration Chemoprophylaxis With Venous Thromboembolism in High-risk Patients With Head and Neck Cancer

Kiranya E Tipirneni et al. JAMA Otolaryngol Head Neck Surg. .

Abstract

Importance: Venous thromboembolism (VTE) is associated with substantial morbidity and is the most common factor associated with preventable death among hospitalized patients. Data from otolaryngologic studies suggest that the risk of VTE may be underestimated among high-risk patients, particularly among those undergoing oncologic procedures. The incorporation of prolonged-duration chemoprophylaxis (PDC) into preventive therapy has been associated with substantial decreases in VTE incidence among patients undergoing oncologic surgery. However, bleeding remains a major concern among otolaryngologists, and substantial variation exists in the use of thromboprophylaxis.

Objective: To assess the association between PDC and VTE in high-risk patients with head and neck cancer undergoing oncologic procedures.

Design, setting, and participants: This retrospective cohort study identified 750 patients with biopsy-confirmed head and neck cancer and a Caprini risk score of 8 or higher who underwent inpatient oncologic surgery at a tertiary care referral center between January 1, 2014, and February 1, 2020. After exclusions, 247 patients were included in the study; patients were divided into 2 cohorts, traditional and PDC, based on the duration of prophylaxis. Univariate and multivariate analyses were performed to examine the development of VTE and bleeding-associated complications during the 30-day postoperative period. Data were analyzed from April 1 to April 30, 2020.

Exposures: PDC, defined as 7 or more postoperative days of chemoprophylaxis.

Main outcomes and measures: VTE and bleeding events during the 30-day postoperative period.

Results: Among 247 patients (mean [SD] age, 63.1 [11.1] years; 180 men [72.9%]) included in the study, 106 patients (42.9%) received traditional prophylaxis, and 141 patients (57.1%) received PDC. The incidence of VTE was 5 of 106 patients (4.7%) in the traditional cohort and 1 of 141 patients (0.7%) in the PDC cohort (odds ratio [OR], 0.15; 95% CI, 0.003-1.33). In the multivariate logistic regression analysis, PDC was independently associated with reductions in the risk of VTE (OR, 0.04; 95% CI, 0.001-0.46). The incidence of bleeding events was 1 of 106 patients (0.9%) in the traditional cohort and 6 of 141 patients (4.3%) in the PDC cohort (OR, 4.64; 95% CI, 0.55-217.00).

Conclusions and relevance: The use of chemoprophylaxis for high-risk patients with head and neck cancer remains a high-priority topic. The results of this study suggest that PDC may be associated with reductions in VTE among this patient population. However, the associated increase in nonfatal bleeding events warrants careful consideration and further highlights the need to determine an optimal duration for chemoprophylaxis among this distinct cohort.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Study Flowchart
LMWH indicates low-molecular-weight heparin; PDC, prolonged-duration chemoprophylaxis; SCD, sequential compression device; and UFH, unfractionated heparin.
See this image and copyright information in PMC

References

    1. Maynard G. Preventing Hospital-Associated Venous Thromboembolism: A Guide for Effective Quality Improvement. 2nd ed. Agency for Healthcare Research and Quality; 2015. AHRQ publication no. 16-0001-EF.
    1. Caprini JA, Scurr JH, Hasty JH. Role of compression modalities in a prophylactic program for deep vein thrombosis. Semin Thromb Hemost. 1988;14(suppl):77-87. - PubMed
    1. Anderson FA Jr, Wheeler HB. Venous thromboembolism. risk factors and prophylaxis. Clin Chest Med. 1995;16(2):235-251. - PubMed
    1. Agnelli G, Bolis G, Capussotti L, et al. . A clinical outcome–based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95. doi:10.1097/01.sla.0000193959.44677.48 - DOI - PMC - PubMed
    1. Torbicki A, Perrier A, Konstantinides S, et al. ; ESC Committee for Practice Guidelines (CPG) . Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276-2315. doi:10.1093/eurheartj/ehn310 - DOI - PubMed